Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Insulin: early-phase trial registry

3 of 7 indexed Insulin trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Insulin: 7 US clinical trials tracked, 3 recruiting.

Insulin is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Pennington Biomedical Research Center, running 1 of these trials.

Enrollment posture brief

Registry condition insulin

OPEN 3 | RECR 43% | LATE 0 | EARLY 3 | RANK #2497 | SPON 1

Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Insulin (this)43%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Insulin

Insulin lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Insulin on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Insulin is recruiting below its size-band peers.

    3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Insulin trials is spread across many organizations.

    Pennington Biomedical Research Center accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Insulin trials plan to enrol fewer than 100 people.

    Median target enrolment is 65 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.

  4. Insulin research is mostly interventional.

    5 interventional and 2 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2

Named interventions

Most-linked intervention names on Insulin records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

LIFE Dietary supplement
1 trials
80 IU NovoLog Insulin aspart into the intranasal mucosa Drug
1 trials
60 IU NovoLog Insulin aspart into the intranasal mucosa Drug
1 trials
40 IU NovoLog Insulin aspart into the intranasal mucosa Drug
1 trials
20 IU NovoLog Insulin aspart into the intranasal mucosa Drug
1 trials
Placebo into the intranasal mucosa Drug
1 trials
CIR-0602K Drug
1 trials
Other Fruit(s) Other
1 trials

US sites by state

Facility locations filed on Insulin trials. A trial with sites in several states counts in each.

Virginia 1 trials
Pennsylvania 1 trials
New York 1 trials
Michigan 1 trials
Maryland 1 trials
Massachusetts 1 trials
Louisiana 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Insulin page

7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Insulin condition card totals 7 registered trials; most-linked intervention LIFE; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.